ENDRA Life Sciences enters ATM equity facility for up to $1.75M through Lucid Capital Markets

ENDRA Life Sciences Inc.

Aggregate gross proceeds up to $1,750,000 from sale of common stock at-the-market.
Lucid Capital Markets acts as sales agent with a 3.0% commission on gross proceeds.
Sales may be made directly on Nasdaq Capital Market or in negotiated transactions.
Agreement effective October 29, 2025; terminates upon full sale, earlier termination, or 3-year anniversary.
Company has no obligation to sell any shares and may suspend or terminate at any time.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.